Table 2

Results of Cox regression analysis of treatment retention

Univariable analysisAdjusted analysis
HR95% CIP valueHR95% CIP value
JAKi to JAKi (ref: JAKi to bDMARD)0.930.79 to 1.100.390.820.68 to 0.990.04
Sex (ref: female)0.860.74 to to 1.030.11
Age1.001.00 to to 1.010.27
Disease duration in years0.990.99 to to 1.000.16
Seropositive, RF or ACPA1.000.85 to 1.170.960.950.81 to 1.110.52
≥1 previous bDMARDs (ref: 0)1.010.85 to 1.200.881.050.88 to 1.260.55
Treatment duration of first JAKi, years1.121.02 to to 1.280.003
Concomitant csDMARD0.730.64 to 0.84<0.0010.730.63 to 0.84<0.001
GC at baseline0.980.83 to 1.150.800.980.83 to 1.150.79
CDAI1.011.00 to to 1.020.14
HAQ-DI1.080.95 to to 1.220.85
Tobacco (ref: never)1.030.86 to 1.240.730.990.82 to 1.200.95
Any comorbidities1.050.91 to 1.220.501.010.85 to 1.190.94
  • Analyses were adjusted for sex, age, disease duration, seropositivity, number of previously used bDMARDs/tsDMARDs, treatment duration of first JAKi, concomitant csDMARD treatment, concomitant GC, HAQ-DI, baseline disease activity values, smoking and comorbidity.

  • ACPA, anticitrullinated peptide antibodies; bDMARD, biologic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GC, glucocorticoid; HAQ-DI, Health Assessment Questionnaire Disability Index; JAKi, Janus kinase inhibitor; ref, reference; RF, rheumatoid factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.